Author(s): Nagorsen D, Kufer P, Baeuerle PA, Bargou R, Nagorsen D, Kufer P, Baeuerle PA, Bargou R, Nagorsen D, Kufer P, Baeuerle PA, Bargou R, Nagorsen D, Kufer P, Baeuerle PA, Bargou R
Abstract Share this page
Abstract For decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the individual disease, monoclonal antibodies, irradiation and/or hematopoietic stem cell transplantation are added. However, the current standard of care--particularly for patients with relapsed disease--is often not sufficient to achieve durable remissions. A highly promising new drug candidate in late-stage clinical development for treatment of B cell malignancies is blinatumomab (MT103 or AMG 103). This bispecific antibody construct has dual specificity for CD19 and CD3 and belongs to the class of bispecific T cell engager (BiTE®) antibodies, which can potentially engage all cytotoxic T cells of a patient for redirected lysis of tumor cells. Here, we review how blinatumomab has so far been pre-clinically and clinically developed for the treatment of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia. Copyright © 2012 Elsevier Inc. All rights reserved.
This article was published in Pharmacol Ther
and referenced in Immunotherapy: Open Access